This study aims to explore the feasibility, safety, and clinical utility of robotic partial resection of pancreatic tumors combined with pancreatic duct repair for the treatment of benign and low-grade malignant pancreatic tumors.

A retrospective review was performed on the clinical records of 103 patients who underwent robotic partial resection of pancreatic tumors at the Pancreatic Surgery Department of Shanghai Changhai Hospital, under the care of a single attending surgeon team, between Aug. 2021 and Nov. 2024.

In 103 patients, 81 underwent pure enucleation with a mean operative time of 36.68±27.63 min and blood loss of 28.86±46.98 ml. There were 2 cases of Grade B postoperative pancreatic fistula (POPF) and 1 case of Grade C POPF. Postoperative abdominal infections occurred in 2 cases, one of which developed pancreatic fistula bleeding on the 20th day after surgery, underwent angiography, and was transferred to the ICU. The patient improved and was discharged after symptomatic and supportive treatment. Eight patients had tumor enucleation with pancreatic duct stent repair, averaging 53.13±33.03 min operation time and 42.50±20.89 ml blood loss. One case had Grade B POPF, and abdominal infection and transient bleeding occurred 13 days after surgery, which improved after continuous irrigation through the drainage tube and symptomatic supportive treatment such as anti-infection. Fourteen patients underwent segmental resection with end-to-end anastomosis, taking 60.86±23.95 min and losing 74.29±37.03 ml blood, without complications. Follow-up (1 month to 3 years) revealed no recurrence, metastasis, or pancreatic dysfunction.

Robotic partial resection of pancreatic tumors for benign and low-grade malignant tumors is a safe, feasible, and effective treatment.